Rezūm Therapy FAQ

Frequent Questions About Rezūm

We are pleased to introduce a new treatment option for men suffering from BPH.

Rezum has undergone rigorous studies and is approved by Health Canada and the US FDA for the treatment of the enlarged prostate and is recommended by the Canadian Urological Association as an alternative and minimally invasive treatment for men with BPH symptoms who are interested in preserving ejaculatory function.
SanoMed is the first clinic to offer Rezūm Water Vapour Therapy in the province of Quebec, and is currently serving patients from all over Eastern Canada and the Atlantic provinces as well. Please see answers to men’s frequently asked questions below, and contact us anytime for more information.

About BPH Treatment with Rezūm

Clinical studies show that many men living with BPH experience symptom relief with Rezūm Water Vapour Therapy. It’s an option for those who’ve given up on watchful waiting and lifestyle changes, men who’ve stopped or don’t want to start taking BPH medications, or men not interested in other minimally invasive or surgical BPH procedures.
Since Rezūm Water Vapour Therapy is a minimally invasive procedure, it can be performed in a doctor’s office, clinic or other out-patient setting.
Rezūm Water Vapour Therapy can be performed under oral sedation or local anesthesia and doesn’t require general anesthesia. Your urologist will discuss your options for maximizing your comfort during the procedure.
Clinical studies show that most men experience symptom relief as soon as 2 weeks after the treatment, and improvements continue for up to 3 months. Patient responses can and do vary.
Clinical studies show that most men return to regular activities within a few days. Your urologist will discuss this with you and make personal recommendations.
Most reported side effects in the clinical study were mild to moderate in severity and typically resolved within a few weeks with the most frequent being urinary symptoms such as frequency, urgency, discomfort during urination or blood in the urine. Erectile and ejaculatory functions were preserved. Most of these events resolve within three weeks of the procedure, but there is a possibility some of these effects may be prolonged. Please talk with your physician about ways to potentially minimize the effects of these risks.

Current clinical studies demonstrate sustained symptom improvement out to 5 years and studies are ongoing to determine longer term patient outcomes.

Most reported side effects in the clinical study were mild to moderate in severity and typically resolved within a few weeks with the most frequent being urinary symptoms such as frequency, urgency, discomfort during urination or blood in the urine. Erectile and ejaculatory functions were preserved. Most of these events resolve within three weeks of the procedure, but there is a possibility some of these effects may be prolonged. Please talk with your physician about ways to potentially minimize the effects of these risks.
There are no reports of new erectile dysfunction as a result of Rezūm treatment. Based on a pivotal study, there is a possibility that an underlying condition may surface following treatment with the Rezūm System. Be sure to talk with your urologist about your individual health situation.
In clinical studies, there were no reports of urinary incontinence as a result of Rezum therapy.

Patients were asked at their 3-month follow-up visit whether they would consider having the Rezūm procedure again if their symptoms were to recur. 90% are likely to have the treatment again if their symptoms recurred after 6 years.

Yes, it received FDA clearance in August 2015 and is also CE marked. The Canadian Urological Association guidelines recommend Rezūm as an alternative treatment for men with BPH symptoms who are interested in preserving ejaculatory function.
No. Only physicians who have been specially trained can treat using the Rezum technology.
Yes, the Rezūm System has been studied in three clinical studies, including first-in-man (FIM) and Pilot Clinical Trials, as well as in a U.S. IDE Pivotal Trial and retrospective study. The studies have been featured in scientific journals such as Research and Reports in Urology, UROLOGY, The Journal of Urology and The Journal of Sexual Medicine. More than 15,000 patients suffering from symptoms of BPH have been effectively treated with the Rezūm System.
This treatment is now available at SanoMed clinic in Montreal, for men from any province or country. SanoMed is the first Quebec provider to offer the therapy, and men come to Montreal for treatment from the Atlantic Provinces and Ontario as well.
Rezūm is indicated for men 40 years or older, with a prostate volume greater than 30cm3.

Next Steps

If you have additional questions about Rezūm please get in touch.

play